Exposure to Infliximab During Pregnancy: Post-Marketing Experience

Overview of attention for article published in Drug Safety, November 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 23 Dimensions

Readers on

mendeley: 85 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 23 publications that cite this research output.

23

The most recent citing publications are shown below. View all 23 publications that cite this research output on Dimensions.

Consenso para la gestión de riesgo en la prescripción de terapias biológicas o de antirreumáticos sintéticos con blanco dirigido: Asociación Colombiana de Reumatología 2023

Article in Revista Colombiana de Reumatología (April 2024)

Safety of biologic agents for the management of rheumatic diseases during pregnancy

Article in Current Opinion in Rheumatology (March 2024)

Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance

Article in British Journal of Dermatology (August 2023)